Novel medical technologies like diagnostic devices, implants, assistive technologies, and surgical tools are likely to emerge from several of the active programs and small business awards of Advanced Research Projects Agency for Health (ARPA-H). To transition to the market, these technologies must first receive authorization from the U.S. Food and Drug Administration (FDA) and then navigate a complex reimbursement process, which requires working with payors and private insurance companies.
In support of this effort, the Investor Catalyst Hub is issuing a network survey to collect expert input from diverse stakeholders. The survey aims to gather insights about the typical pathways, exemplars, and specific challenges facing the reimbursement of medical technologies.
All survey responses are due by Friday, February 21, 2025.
Massachusetts is home to ARPA-H’s Investor Catalyst Hub. Massachusetts-based organizations can join the Hub’s nationwide network of spokes collectively working to speed the commercialization of groundbreaking health solutions.
